Shared decision making with brain tumor patients
- Conditions
- Adult patients with meningioma (50%) or low- (20%) or high-grade (30%) glioma.
- Registration Number
- NL-OMON23658
- Lead Sponsor
- Elisabeth Twee-Steden Ziekenhuis Tilburg (The Netherlands), Tilburg University (The Netherlands).
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
In order to be eligible to participate in this study a participant must meet all of the following criteria:
1) Adult patients (>18 years of age) with meningioma or low- or high-grade glioma who visit the neurosurgical clinic and (from the second year onwards) who are willing and able to use the Goings-On application.
2) Fluent in Dutch.
1) Being a participant in another clinical study that may induce potential contamination of the effects of the other study.
2) Unable physically and/or mentally to fill out the app on a daily basis (a minute a day) and/or fill out (digital) questionnaires.
3) Not agreeing to participate in the evaluations and/or to the use of the related data, and/or to sign for informed consent to use the data from the Goings-On app for this study.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We will evaluate differences in measures of shared decision-making, aspects of quality of life, and symptoms of anxiety and depression in patients after the implementation of the Goings-On app as compared to the baseline. Furthermore, we will audiotape the first neurosurgical consultation (and the first neuro-oncological consultation will also be audiotaped for most glioma patients) to evaluate differences in content of information discussed and duration of the consultation after the implementation of the Goings-On app as compared to the baseline.
- Secondary Outcome Measures
Name Time Method As secondary outcomes, we will evaluate the symptoms and personal life goals recorded in the Goings-On app, the frequency and extent of the use of the app by brain tumor patients and their characteristics; as well as the usage of the dashboard by the clinical team, for which patients they use the dashboard, and draw a comparison of the characteristics of the patients for which they use it more versus less.